Kyowa Hakko
Active Pharmaceutical Ingredients

Japanese pharmaceutical companies are experiencing dramatic changes in business conditions. To facilitate the development of patient-centered medicine, Japan’s health care system is undergoing reform, and laws regulating the pharmaceutical industry are being revised. Against this backdrop, drug prices have peaked due to the Japanese government’s measures to curb health care expenses, while the cost of drug development is rising. Moreover, mergers and acquisitions among pharmaceutical companies are reshaping the industry, and major overseas pharmaceutical companies are making inroads into the domestic market. In response to these business conditions, Kyowa Hakko will develop new drugs that meet medical needs by concentrating management resources on its key areas of competence in cancer, allergies, the central nervous system, and such core technologies as antibodies. At the same time, our goal is to provide high-quality medical information that contributes to the spread of evidence-based medicine and earns us the trust of patients, physicians, and caregivers.

For more information, click here or contact us.